Following the vote, the British government confirmed that it would make an 'appropriate financial contribution' in return for this level of participation. The vote was more than welcomed by the British BioIndustry Association , the Association of the British Pharmaceutical Industry and the Drug Safety Research Unit, DRSU.
In a joint statement on behalf of the pharmaceutical industry in the UK, Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, and Steve Bates, chief executive of the BioIndustry Association, said:
“Today, Parliament has sent a clear message that patients and public health should be a top priority for the Government in these negotiations. Every month, 37 million packs of medicine arrive in the UK from the EU and 45 million move the other way. Therefore, it is essential that the UK continues to participate in the EMA after Brexit, as set out in the Brexit White Paper and in the Prime Minister’s Mansion House speech.”